Menu

非布司他在国内的价格

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Febuxostat tablets are a drug used to treat ventilation. It was developed and authorized by Teijin Pharmaceutical of Japan. In April 2008, febuxostat (febuxostat, feburic) was approved for marketing in Europe. In February 2009, the FDA approved febuxostat (febuxostat, feburic) for marketing. On June 26, 2013, febuxostat was officially launched in China. What is the price of febuxostat in China?

The domestic price of febuxostat is 10 yuan per tablet, 40mg/tablet. The recommended dosage of febuxostat is 40mg/day, which means that febuxostat will cost about 300 yuan a month. For those who cannot tolerate febuxostat, the dosage may need to be increased to 80mg/day, which means two tablets a day, about 600 yuan a month.

Febuxostat produced by Zydus Pharmaceutical Factory in India has the same efficacy as the original drug, but the price is indeed much lower. The specification is 80mg*30 tablets/box. Its price is about 80$, and the specification is 40mg*100 tablets/box and the price is about 200$.

Febuxostat is a new type of selective non-purine xanthine oxidase (XO) inhibitor. The main component is febuxostat. Febuxostat is a newly developed drug, and at the same dose, febuxostat has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of gout acid-lowering drugs, many patients prefer febuxostat.

Currently, there are more than 20 phase III clinical trials of febuxostat that have been conducted or are ongoing in my country. Although febuxostat has a relatively good effect in treating gout, due to the short time it has been on the market in China, there are few reports on clinical applications and adverse reactions after use. Febuxostat still carries risks of allergic reactions, liver and kidney toxicity, and adverse cardiovascular events, so patients should closely monitor changes in liver and kidney function during use. If a patient experiences a serious adverse event while taking febuxostat, he/she needs to communicate with the attending physician promptly for timely treatment.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。